Equities research analysts expect Adamis Pharmaceuticals Corp (NASDAQ:ADMP) to report sales of $4.05 million for the current quarter, Zacks reports. Two analysts have issued estimates for Adamis Pharmaceuticals’ earnings, with the highest sales estimate coming in at $4.50 million and the lowest estimate coming in at $3.60 million. The business is scheduled to issue its next quarterly earnings results on Thursday, March 29th.
According to Zacks, analysts expect that Adamis Pharmaceuticals will report full year sales of $4.05 million for the current financial year, with estimates ranging from $13.80 million to $14.73 million. For the next year, analysts anticipate that the business will post sales of $20.05 million per share, with estimates ranging from $18.40 million to $21.69 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Adamis Pharmaceuticals.
A number of research firms have recently weighed in on ADMP. B. Riley set a $10.00 price objective on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, November 15th. Zacks Investment Research raised shares of Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Maxim Group set a $14.00 price objective on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, December 5th. ValuEngine lowered shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 30th. Finally, Raymond James Financial set a $7.00 price objective on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, February 23rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $7.33.
Several large investors have recently bought and sold shares of ADMP. B. Riley Financial Inc. acquired a new position in shares of Adamis Pharmaceuticals in the fourth quarter valued at approximately $1,022,000. Vanguard Group Inc. grew its holdings in Adamis Pharmaceuticals by 22.2% in the second quarter. Vanguard Group Inc. now owns 942,940 shares of the specialty pharmaceutical company’s stock valued at $4,903,000 after purchasing an additional 171,167 shares during the period. EAM Investors LLC grew its holdings in Adamis Pharmaceuticals by 58.3% in the third quarter. EAM Investors LLC now owns 371,732 shares of the specialty pharmaceutical company’s stock valued at $1,942,000 after purchasing an additional 136,970 shares during the period. Virtu Financial LLC purchased a new stake in Adamis Pharmaceuticals in the fourth quarter valued at approximately $442,000. Finally, Granite Investment Partners LLC purchased a new stake in Adamis Pharmaceuticals in the third quarter valued at approximately $457,000. 12.42% of the stock is owned by institutional investors and hedge funds.
Adamis Pharmaceuticals (NASDAQ:ADMP) traded up $0.18 during trading hours on Friday, hitting $3.80. 984,814 shares of the stock were exchanged, compared to its average volume of 812,318. The company has a current ratio of 3.93, a quick ratio of 3.79 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $129.57, a price-to-earnings ratio of -5.46 and a beta of 0.36. Adamis Pharmaceuticals has a twelve month low of $2.35 and a twelve month high of $6.45.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/03/14/adamis-pharmaceuticals-corp-admp-expected-to-announce-quarterly-sales-of-4-05-million.html.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.